CAMBRIDGE, UK– 2 November 2020 – Mission Therapeutics, a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), has appointed Dr Suhail Nurbhai as Chief Medical Officer (CMO) with immediate effect. Dr Nurbhai has more than 25 years of experience and a strong track record in the strategic and operational leadership of […]

LONDON AND CAMBRIDGE, UK – 7 July 2020 – Working in close collaboration, scientists from the Tate Group, Imperial College London, and drug discovery and development company, Mission Therapeutics (“Mission”), have discovered the first exquisitely selective probe for a deubiquitylating enzyme (DUB). The research has been published in the leading peer-reviewed Journal of the American […]

CAMBRIDGE, UK – 3 December 2019 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), and AbbVie (“AbbVie”)(NYSE: ABBV), a global, research-driven biopharmaceutical company, today announced the identification of several DUBs as potential drug targets in their Alzheimer’s and Parkinson’s R&D collaboration. AbbVie has nominated the panel […]

CAMBRIDGE, UK – 16 September 2019 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), announced today that its collaboration with research-based global biopharmaceutical company, AbbVie (“AbbVie”)(NYSE: ABBV), has been shortlisted for the 2019 Scrip Best Partnership Alliance Award. Mission and AbbVie are working together in the […]

CAMBRIDGE, UK – 3 December 2018 –Mission Therapeutics, a drug discovery and development company focused on treating mitochondrial diseases, fibrosis and neurodegenerative disorders by selectively inhibiting deubiquitylating enzymes (DUBs), has appointed Dr Nick Edmunds as Vice President, Head of DUB Discovery, with immediate effect. Dr Edmunds has over 15 years’ pharmaceutical industry experience and a […]